{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-062154","form_type":"8-K","ticker":"BMEA","cik":"0001840439","company_name":"Biomea Fusion, Inc.","filed_at":"2024-03-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.911109+00:00","generated_at":"2026-06-05T01:53:33.074855+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Biomea Fusion presents COVALENT-111 data: up to 1.4% placebo-adjusted HbA1c reduction at Week 26 off therapy","bullets":["Placebo-adjusted mean HbA1c reduction up to 1.4% at Week 26 after 28-day BMF-219 treatment.","100mg and 200mg dose levels selected for expansion phase; 12-week dosing, follow-up to Week 52.","No serious adverse events or study discontinuations; no symptomatic hypoglycemia.","Expansion phase enrolling on schedule; initial 26-week data expected 2H24.","Biomea plans to announce COVALENT-112 T1D update in Q4 2023 earnings release."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-062154","json":"https://secwatch.observer/filing/0001193125-24-062154.json","markdown":"https://secwatch.observer/filing/0001193125-24-062154.md","text":"https://secwatch.observer/filing/0001193125-24-062154.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840439/000119312524062154/0001193125-24-062154-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840439/000119312524062154/d802391d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T01:53:33.074855+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}